1	Dif	ferential symptoms among COVID-19 outpatients before and during periods of SARS-
2	Co	V-2 Omicron variant dominance in Blantyre, Malawi: a prospective observational study
3		
4	Ma	rrah G. Chibwana <sup>1+</sup> , Herbert W. Thole <sup>1+</sup> , Cat Anscombe <sup>1,3+</sup> , Philip M. Ashton <sup>1,2</sup> , Edward
5	Gre	een <sup>3</sup> , Kayla G. Barnes <sup>1,2,4,5,6</sup> , Jen Cornick <sup>1,2</sup> , Ann Turner <sup>2</sup> , Desiree Witte <sup>1,2</sup> , Sharon Nthala <sup>1</sup> ,
6	Chi	kondi Thom <sup>1</sup> , Felistas Kanyandula <sup>1</sup> , Anna Ainani <sup>1</sup> , Natasha Mtike, Hope Tambala <sup>7</sup> ,
7	Vei	ronica N'goma <sup>1</sup> , Dorah Mwafulirwa <sup>1</sup> , Erick Asima <sup>1</sup> , Ben Morton <sup>3</sup> , Markus Gmeiner <sup>1</sup> ,
8	Zaz	iwe Gundah <sup>7</sup> , Gift Kawalazira <sup>7</sup> , Neil French <sup>2</sup> , Nicholas Feasey <sup>1,3</sup> , Robert S. Heyderman <sup>8</sup> ,
9	Тос	dd D Swarthout <sup>8</sup> , Kondwani C. Jambo <sup>1,3,9</sup> *
10		
11	1.	Malawi-Liverpool-Wellcome Clinical Research programme (MLW), Blantyre, Malawi
12	2.	Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool,
13		Liverpool, United Kingdom
14	3.	Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United
15		Kingdom
16	4.	Harvard School of Public Health, Boston, USA
17	5.	Broad Institute of MIT and Harvard, Cambridge, USA
18	6.	University of Glasgow MRC Centre for Virus Research, Glasgow, UK
19	7.	Blantyre District Health Office, Ministry of Health, Blantyre, Malawi
20	8.	NIHR Global Health Research Unit on Mucosal Pathogens, Research Department of
21		Infection, Division of Infection and Immunity, University College London, London, UK
22	9.	Kamuzu University of Health Sciences (formerly University of Malawi-College of
23		Medicine) Blantyre, Malawi
24		
25	*Co	orresponding author
26	Em	ail: Kondwani.Jambo@lstmed.ac.uk or kjambo@mlw.mw (KCJ)
27	+ C	ontributed equally to this manuscript
28		
29	Ma	in text: 2717 words
30		
31		nning title: Changes in symptoms from Pre-Omicron to Omicron variants TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 32 ABSTRACT

Background. It is widely reported that the SARS-CoV-2 Omicron variant has resulted in high 33 34 number of cases, but relatively low incidence of severe disease and deaths, compared to the 35 pre-Omicron variants of concern. We aim to assess the differences in symptom prevalence 36 between Omicron and pre-Omicron infections in a sub-Saharan African population. Methods. In this cross-sectional observational study, we collected data from children and 37 38 adult outpatients presenting at two primary healthcare facilities in Blantyre, Malawi. Eligible 39 participants were aged >1month old, with signs suggestive of COVID-19, and those not suspected of COVID-19. Nasopharyngeal swabs were collected for SARS-CoV-2 PCR testing 40 41 and positive samples whole genome sequenced to identify the infecting variant. The 42 primary outcome was the likelihood of presenting with a given symptom in individuals 43 testing positive during the period in which Omicron-dominated (December 2021 to March 44 2022) with those infected during the pre-Omicron period (August 2021 to November 2021). 45 Findings. Among 5176 study participants, the median age was 28 years (IQR 21-38), of 46 which 6.4% were under 5, 9.2% were 6 to 17 years, 77% were 18 to 50 years, and 7.1% were above 50 years old. Prevalence of SARS-CoV-2 infection was 23% (1187/5188), varying over 47 48 time, with peaks in January 2021, July 2021 and December 2021, driven by the Beta (B.1.351), Delta (B.1.617.2) and Omicron (BA.1/2) variants, respectively. Headache (OR 49 50 0.47[CI 0.29 – 0.79]), cough (OR 0.37[CI 0.22 – 0.61]), fatigue (OR 0.20[CI 0.08 – 0.48]) and 51 abdominal pain (OR 0.38[Cl 0.18 – 0.78]) were less common in participants infected during the Omicron-dominant period than during pre-Omicron period. Fever was more common in 52 participants infected during the Omicron-dominated period than during pre-Omicron period 53 (OR 2.46[Cl 1.29 – 4.97]). COVID-19 vaccination, accounting for number of doses and days 54 55 since last dose, was not associated with a reduced risk of PCR-confirmed SARS-CoV-2 56 infection (1 dose, OR 1.10[Cl 0.39 – 2.66]; 2 doses, OR 1.11[Cl 0.40 – 2.57]; all p=0.8). 57 **Interpretation.** In this Malawian population, the prevalence of clinical symptoms associated with Omicron infection differ from those of pre-Omicron infections and may be harder to 58 identify clinically with current symptom guidelines. To maintain robust surveillance for 59 60 COVID-19 and emerging variants, case definitions and testing policies will need to be 61 regularly reviewed to ensure case ascertainment.

- 62
- 63

## 64 INTRODUCTION

As of June 2022, the COVID-19 pandemic has resulted in 543 million cases and 6.3 million 65 66 deaths globally <sup>1</sup>. In sub-Saharan Africa, the pandemic has however been associated with a 67 lower rate of hospitalisation and deaths than in Europe and the Americas <sup>1</sup>, despite widespread SARS-CoV-2 community transmission<sup>2</sup>, and low COVID-19 vaccine coverage<sup>3</sup>. 68 69 Due to the continued emergence of SARS-CoV-2 variants of concern, surveillance is essential 70 for monitoring the pandemic and informing public health interventions, however the 71 optimal approach to surveillance in low-income, resource-poor settings is unclear <sup>4</sup>. 72 73 By June 2022, Malawi had experienced four epidemic waves peaking in July 2020, January 74 2021, July 2021, and December 2021. There were 86,348 confirmed SARS-CoV-2 cases 75 nationally, with 2,645 COVID-19-associated deaths <sup>1</sup>. However, due to the availability of testing there is considerable case under ascertainment, as evidence by the high 76 77 seroprevalence of >65% observed in Malawi as of July 2021<sup>5</sup>. Blantyre has had the highest number of reported COVID-19 cases in Malawi, with 28.6% of the national cases <sup>6</sup>. Recently. 78 79 the Omicron variant has resulted in less hospitalisations and mortality in Malawi compared 80 to the Delta variant <sup>1</sup>, which has coincided with high seroprevalence of SARS-CoV-2 antibodies in Malawi and across sub-Saharan Africa <sup>5,7</sup>. Further, Malawi introduced COVID-81 82 19 vaccines in March 2021<sup>8</sup>. The COVID-19 vaccination coverage for Malawi is 4.5%, including the AstraZeneca, Janssen and Pfizer vaccines, with AstraZeneca vaccine 83 constituting most of the doses <sup>8</sup>. 84

85

Using data from early in the pandemic, a standardised case definition for COVID-19 was 86 developed by the World Health Organisation (WHO)<sup>9</sup> and United States Centre for Disease 87 Control (US CDC)<sup>10</sup>, and these have allowed targeted SARS-CoV-2 testing. However, there 88 89 has been limited systematic data collected on clinical presentation of SARS-CoV-2 infection 90 in sub-Saharan African settings, outside of South Africa. This is particularly important as there is a high burden of other febrile illnesses such as malaria, pneumonia, TB and 91 salmonellosis that have clinical features that overlap with COVID-19<sup>11,12</sup>. Further, there is 92 93 limited data on the differences in clinical presentation between infections caused by 94 different variants of concern (VOC), especially amongst non-hospitalised patients. To 95 address these gaps, our study measured the prevalence of PCR-confirmed SARS-CoV-2

96	infection among outpatients presenting with medical conditions at primary healthcare
97	facilities and compared the symptom profiles between Omicron and pre-Omicron infections.

98

## 99 METHODS

#### 100 Study design and population

From November 2020 to March 2022, we conducted a SARS-CoV-2 prevalence study in 101 102 primary healthcare facilities in the city of Blantyre, southern Malawi. Blantyre is Malawi's 103 commercial city with a population of 800,264 (pop density, 3334/km<sup>2</sup>). Adults and children 104 were recruited voluntarily from two government-owned primary healthcare facilities, 105 Ndirande Health Centre and Limbe Health Centre, both overseen by the Blantyre District 106 Health Office. Census data shows Ndirande HC serves a catchment area of 135,736, while 107 Limbe HC serves a catchment area of 145,604, but the actual catchment is likely much 108 higher.

109

110 From November 2020 to July 2021, individuals with medical conditions were screened at the facility's outpatient services department. Following assessment by a clinician and a review 111 112 of the individual's health passport (patient retained medical record), a nasopharyngeal swab was collected for SARS-CoV-2 screening by SARS-CoV-2 by RT-PCR from patients suspected 113 114 of COVID-19 according to the WHO case definition <sup>9</sup>. From August 2021, following a protocol amendment to include capturing a more detailed clinical history using the ISARIC symptom 115 list <sup>13-15</sup>, participants included both those suspected and those not suspected of COVID-19 116 117 according to the WHO case definition, with a 2:1 numerical bias towards those with suspected COVID-19. Patients with suspected COVID-19 were recruited as and when they 118 119 presented to the facility, while those with not clinically suspected of COVID-19 were 120 selected by approaching every third patient in health facility's triage area. 121 Data and specimen collection 122 Following informed consent and assent (for children) from August 2021, we used an 123 abridged International Severe Acute Respiratory and Emerging Infection Consortium 124 125 (ISARIC) Clinical Characterisation Protocol (CCP) electronic case report form (eCRF) <sup>13-15</sup> to

- 126 collect demographic and clinical data from all participants. Study nurses collected
- 127 nasopharyngeal swabs in Universal Transport Medium (UTM) (Copan, Brescia, Italy) from all

- 128 participants. Samples were initially stored and transported to the Malawi-Liverpool-
- 129 Wellcome Programme (MLW) laboratory on ice and processed within 48 hours.
- 130

#### 131 Laboratory testing

Nasopharyngeal swabs were tested for SARS-CoV-2 RNA using the CDC 2019-nCoV RNA RT-132 PCR diagnostic panel (Integrated DNA Technologies, Iowa, USA). A cycle threshold (Ct) value 133 of <40 was considered positive for SARS-CoV-2 using QuantStudio Real-Time PCR software 134 v1.3 (Applied Biosystems, UK). Ribonuclease protein was used as an internal control to 135 identify presence of human RNA. A negative extraction control and a PCR no-template 136 137 control were also performed with every test. The results of patients with positive PCR tests 138 were shared with the Blantyre District Health Office for further follow up and patient 139 management.

140

## 141 Genomic sequencing and analysis

142 Samples were extracted using the Qiasymphony-DSP mini kit 200 (Qiagen, UK) with offboard 143 lysis. Samples were then tested using the CDC N1 assay to confirm the Ct values before 144 sequencing. Samples with a Ct value <27 were sequenced. The following sequencing protocols were used; ARTICv2 and v3 was used from November 2020 from July 2021 to July 145 146 2021<sup>16</sup> and UNZA<sup>17</sup> from August 2021 on wards. Initially two primer pools were used, however a third pool was made for primer pairs that commonly had lower depth compared 147 to the average <sup>15</sup>. PCR cycling conditions were adapted to the new sequencing primers, with 148 149 annealing temperature changed to 60°C. Sequencing was carried out with the Oxford 150 Nanopore Technologies MinION sequencer. Samples that had poor coverage (<70%) with 151 the ARTIC primer set were repeated with the UNZA primer set. 152

153 For analysis of sequencing data, the lineage of each consensus genome was identified using

- 154 pangolin with the following versions; pangolin v3.1.17, pangolearn 2021-12-06,
- 155 constellations v0.1.1, scorpio v0.3.16, pango-designation used by pangoLEARN/Usher
- 156 v1.2.105, pango-designation aliases v1.2.122<sup>18</sup>. Samples were re-analysed when the
- 157 Pangolin database was updated. The run was repeated if there was contamination in the
- 158 negative control.
- 159

#### 160 Statistical analysis

- 161 We performed statistical analyses and graphical presentation using R statistical package,
- 162 version 4.1.0. Categorical variables were summarised using frequency distributions and
- 163 compared using Pearson's Chi-squared test and Fisher's exact test. The continuous variables
- 164 were presented as median with interquartile range.
- 165
- 166 We employed multivariable logistic regression models, as implemented in the R package
- stats (version 3.6.2), to investigate odds of presenting with particular symptoms in Omicron
- 168 compared pre-Omicron phases, adjusting for age and sex. A multivariable logistic regression
- 169 model adjusting for age, sex, vaccination status, vaccination doses and days since last
- 170 vaccine dose was also employed to investigate the impact of COVID-19 vaccination on PCR-
- 171 confirmed SARS-CoV-2. P-values <0.05 were considered significant.
- 172

## 173 Ethics approval

- 174 The study was approved by the College of Medicine Research and Ethics Committee
- 175 (COMREC P.08/20/3099) and Liverpool School of Tropical Medicine Research Ethics
- 176 Committee (LSTMREC 21-058).
- 177

#### 178 **RESULTS**

## 179 Demographic and clinical characteristics of participants

180 From November 2020 through March 2022, 6147 (Ndirande Health Centre, n=2899; Limbe 181 Health Centre, n=3248) individuals were approached, and 5188 participants were enrolled but 12 were excluded as they did not have sex recorded. Refusals were mostly from parents 182 183 or guardians who did not consent for their children to undergo nasopharyngeal swabbing, and this did not change throughout the study period. Overall, the participants' median age 184 was 28 years (IQR 21-38), of which 6.4% (331/5176) were under 5 years, 9.2% (331/5176) 185 were 6 to 17 years (479/5176), 77% (4000/5176) were 18 to 50 years, and 7.1% (368/5176) 186 187 were above 50 years old. Of the total 50% (2596/5176) were female (table 1).

188

## 189 Prevalence of SARS-CoV-2 infection and genomic surveillance

190 The overall prevalence of PCR-confirmed SARS-CoV-2 infection was 23% (1187/5176) (table

191 1). SARS-CoV-2 prevalence varied over time, with three distinct peaks over the study period,

192	namely January 2021, July 2021, and December 2021 (figure 1A). SARS-CoV-2 prevalence
193	was lowest in those under 5 years of age (5.74% [CI 3.49 – 8.82]) compared to all other age
194	groups (6-12yrs, 16.7% [12.1 – 22.2]; 13-17yrs, 25.3% [20.0 – 31.2]; 18-50yrs, 24.5% [23.2 –
195	25.9]; 50+yrs, 22.8% [18.6–27.5) (figure 1B). The three prevalence peaks corresponded with
196	emergence of variants of concern (VOC), including Beta (B.1.351; January 2021), Delta
197	(1.617.2; July 2021) and Omicron (BA.1/2; December 2021) (figure 1C). Only Omicron (BA.1)
198	was detectable in all age groups (figure 1D).
199	
200	Symptoms associated with SARS-CoV-2 infection, pre- and during the Omicron-dominated
201	phase
202	Forty-nine percent (2520/5176) of the total participants were recruited from August 2021 to
203	March 2022, hence had detailed symptom and medical history (Supplementary figure 1).
204	Out of these 2509 had complete symptomology data and were used in the subsequent
205	analysis. Using a multivariable analysis, cough (71% vs 68%, risk ratio, 1.50; 95% CI, 1.00 to
206	2.30, p=0.056), fatigue (14% vs 6.3%, risk ratio, 2.27; 95% CI, 1.29 to 3.86, p=0.003) and
207	headache (49% vs 37%, risk ratio, 1.64; 95% CI, 1.15 to 2.34, p=0.007) were associated with
208	a high risk of PCR-confirmed SARS-CoV-2 infection during the pre-Omicron period (table 2).
209	While, during the Omicron-dominated period, only headache (39% vs 30%, risk ratio, 1.41;
210	95% CI, 1.07 to 1.86, p=0.015) was associated with a high risk of PCR-confirmed SARS-CoV-2
211	infection.

212

## 213 Impact of COVID-19 vaccination on the risk of PCR-confirmed SARS-CoV-2 infection

214 Eighty percent (2009/2520) of the participants with detailed symptomology were eligible for vaccination (18 years and above) and had complete vaccination history. We, therefore, used 215 216 these individuals to determine whether the risk of PCR-confirmed SARS-CoV-2 infection was 217 different between vaccinated compared to unvaccinated adults. Using a multivariable 218 analysis, adjusting for days since last vaccine dose, sex, age and recruitment period; COVID-219 19 vaccination was not associated with a reduced risk of PCR-confirmed SARS-CoV-2 infection (1 dose, OR 1.10[CI 0.39-2.66]; 2 doses, OR 1.11[CI 0.40-2.57]; <91 days, OR 1.93[CI 220 221 0.74-5.68]; 91+ days, OR 1.54[CI 0.63-4.34]) (table 3). However, the recruitment period of 222 December 2021 to March 2022 (Omicron), was associated with a threefold increase in the

223 risk of PCR-confirmed SARS-CoV-2 infection than the August 2021 to November 2021 (pre-Omicron) period (OR 2.56 [CI 2.02-3.26]) (table 3). 224

225

#### 226 Symptoms associated with PCR-confirmed SARS-CoV-2 infection change with variants 227 Based on the genomic surveillance data (figure 1C), we assigned all individuals infected 228 within the period from August 2021 to November 2021 as pre-Omicron infections (most 229 commonly Delta infections), and those from December 2021 to March 2022 as Omicron 230 infections. Twenty two percent (447/2009) of vaccine-eligible patients who had provided 231 the date since last vaccine dose had PCR-confirmed SARS-CoV-2 infection (table 4), while 35 232 out of 228 patients were less than 18 years of age and had PCR-confirmed SARS-CoV-2 233 infection (supplementary table 1), as such subsequent analyses focused on the adult 234 population (18 years and above). Fifty percent (151/302) of these patients in Omicron phase 235 were female, while 56% (81/145) were female in the pre-Omicron phase. The median age of 236 patients from the two phases was similar (31 years [IQR 25-38] vs. 32[IQR 23-39], p=0.8) 237 (table 4). Among those with known self-reported HIV status, the HIV prevalence was 16%, 238 which was similar between the two phases (17% vs 13%, p=0.4). Of those People Living with 239 HIV (PLHIV), 97% (34/35) in the Omicron phase and 94% (15/16) in the pre-Omicron phase 240 were on antiretroviral therapy. Other chronic illnesses were uncommon, with only 1.6% 241 (7/447), 0.9% (4/447) and 3.4% (15/447) self-reported to have hypertension, diabetes, and asthma, respectively, although hypertension and diabetes, in particular, are widely 242 underdiagnosed in Malawi <sup>19,20</sup>. Thirty-one percent (137/447) of the participants reported 243 being vaccinated with at least one dose of the COVID-19 vaccine (AstraZeneca vaccine (80% 244 (109/137)) or Janssen vaccine (20% (28/137)). Of which, 54% (74/447) had self-reported to 245 246 have received at least two doses of the AstraZeneca vaccine, with more patients in the Omicron phase than the pre-Omicron phase (20% (59/302) vs. 10% (15/145), p=0.025). 247 Moreover, the days since last vaccine dose were longer in the Omicron phase than pre-248 249 Omicron phase (173[IQR 141-208] vs. 78[IQR 40-137], p<0.001). 250

251 Clinical symptoms associated with PCR-confirmed SARS-CoV-2 infections were different

- 252 during the Omicron and pre-Omicron phases (table 5). Cough (70% vs. 54%, p<0.001),
- 253 fatigue (14% vs 3.6%, p<0.001), loss of taste (10% vs. 5.0%, p=0.033), headache (50% vs.
- 254 39%, p=0.034), and abdominal pain (14% vs. 8.3%, p=0.043) were more frequent in patients

- 255 from the pre-Omicron phase compared to the Omicron phase. In contrast, muscle ache was
- 256 more common in the Omicron phase than pre-Omicron phase (35% vs 25%, p=0.029).
- 257
- 258 Controlling for age, sex and COVID-19 vaccination status in a multivariable analysis, cough
- 259 (OR 0.37 [Cl 0.22 0.61], p<0.001), fatigue (OR 0.20 [Cl 0.08 0.48], p<0.001), headache (OR
- 260 0.47 [CI 0.29 0.79], p=0.001), and abdominal pain (OR 0.38 [CI 0.18 0.78) were
- 261 independently associated with pre-Omicron than Omicron SARS-CoV-2 PCR positive
- diagnosis (figure 2 and table 5). Conversely, fever was independently associated with
- 263 Omicron than pre-Omicron SARS-CoV-2 PCR positive diagnosis (OR 2.46 [Cl 1.29 4.97])
- 264 (figure 2 and table 5).
- 265

#### 266 **DISCUSSION**

- 267 In a setting where there is a high burden of presentations with infectious disease, we found
- that the symptoms associated with SARS-CoV-2 Omicron infection have become
- 269 considerably less distinct, differing significantly from those infections with pre-Omicron
- 270 variants (predominantly Delta). Indeed fever, which is common to many infectious
- 271 presentations <sup>11,12</sup>, was most prevalent among presumed Omicron infected patients, while
- 272 headache, cough, fatigue, and abdominal pain were significantly more prevalent among pre-
- 273 Omicron cases.
- 274

Our data showing a different symptom profile associated with Omicron infection is 275 consistent with studies elsewhere <sup>21</sup> with headache being prominent in three other studies 276 277 from the UK<sup>21-23</sup>. However, we observed high odds for presenting with fever in presumed 278 Omicron-infected patients than pre-Omicron patients, in contrast with the two studies in 279 the UK <sup>21,23</sup>. The main differences between the Malawi study and the UK studies are age and 280 prevalence of Omicron sub-lineages, with Malawi cohort being a younger population and 281 having predominantly BA.1 at time of sampling. BA.1 is associated with a different symptom profile than BA.2<sup>22</sup>. Together, our findings and those of others suggest that the clinical case 282 283 definition of COVID-19 used for testing and surveillance may need to be revised to maintain 284 case ascertainment.

286 Data from Malawi and elsewhere has shown that the Omicron variant has presented with less severe disease, hospitalisation and deaths, than the pre-Omicron VOCs <sup>1,24</sup>. The 287 288 Omicron variant have been shown to be less capable of transition from the upper to lower respiratory tract infection <sup>25</sup>, and this could potentially contribute to the low incidence of 289 290 severe disease. However, data in non-immunised populations in Hong Kong indicate that Omicron is not intrinsically mild <sup>26,27</sup>, suggesting that immune response or past exposure 291 292 could be an important determinant of this low severity. Data from South Africa has shown that high SARS-CoV-2 seroprevalence has been associated with low number of deaths and 293 hospitalisation attributed to the Omicron variant <sup>24</sup>. In Malawi, seroprevalence data has 294 295 shown that more than 70% of the population had anti-SARS-CoV-2 receptor binding domain 296 (RBD) antibodies before the Omicron variant pandemic wave <sup>5</sup>, reaching over 90% at the 297 peak of the Omicron wave in January 2022 (unpublished). In line with previous findings <sup>28</sup>, 298 COVID-19 vaccination was not associated with a reduced risk of PCR-confirmed SARS-CoV-2 299 infection, especially during the Omicron wave. It is therefore plausible that the altered 300 clinical presentation observed in our study could also be attributed to pre-existing immunity 301 from prior SARS-CoV-2 exposure.

302

Furthermore, our findings align with the temporal dynamics of the COVID-19 pandemic 303 304 waves in Malawi and the region <sup>1,5,24</sup>. A high SARS-CoV-2 prevalence of 30-50% among patients presenting to primary healthcare at the peak of the three pandemic waves, is 305 306 consistent with high reported national COVID-19 cases during the same period <sup>1</sup>. Furthermore, consistent with genomic surveillance <sup>15,29</sup>, our sentinel surveillance correctly 307 identified the VOCs driving the local pandemic waves. Due to the consistency in our 308 309 sampling over time, we were able to provide real-time data to aid public health response in 310 Malawi, especially on the identification of VOCs driving community transmission (unpublished). Collectively, this indicates that sentinel surveillance backed up by diagnostics 311 312 and genomics data could be an early warning system for national pandemic response in 313 resource-limited settings, considering that by the time hospitalisations are rising it is already 314 too late to intervene effectively.

315

Our study had several limitations. Firstly, the study was conducted in urban Blantyre andfindings may not be generalisable to rural settings. Secondly, our study cohort (median age

- 318 28 years [IQR 21-38]) was not fully representative of the population structure in Malawi
- 319 (median age 17.5 years) <sup>30</sup>. Thirdly, since our genomic surveillance was limited to a subset of
- 320 samples with low PCR CT values, this approach biases our identification of variants to those
- 321 causing high viral burden infections at time of recruitment.
- 322
- 323 In conclusion, our study demonstrates changes in clinical symptoms overtime, aligned to
- 324 infecting variant, indicating that case definitions of COVID-19 need constant monitoring and
- 325 revision to match SARS-CoV-2 evolution to maintain its relevance for institutional and
- 326 national testing policies. This study also highlights the importance and utility of sentinel
- 327 surveillance in low-resourced settings to aid timely public health response against the
- 328 COVID-19 pandemic and future pandemics.
- 329

## 330 NOTES

## 331 Author contributions

- 332 Conceptualization of study: RSH, NF, TS, MGC, KCJ
- 333 Study design: RSH, NF, TS, MGC, KCJ
- 334 Data collection: SN, CT, FK, AA, NM
- 335 Laboratory testing: CA, KB, JC
- 336 Data analysis: PMA, KCJ
- 337 Accessed and verified the underlying data: HWT, KCJ
- 338 Study management: HWT, MG, HT, VN, DM, EA
- 339 Manuscript writing: MGC, HWT, KCJ, NF
- 340 Manuscript review and approval: All authors
- 341

## 342 ACKNOWLEDGEMENTS

- 343 The authors thank all participants whose samples are used in this study. We thank the MLW
- Clinical Research Support Unit (CRSU) team for supporting this study.
- 345

#### 346 **DISCLAIMER**

- 347 The findings and conclusions in this report are those of the authors and do not necessarily
- 348 represent the official position of the funders.
- 349

## 350 FUNDING

- 351 The work is supported by funding from Wellcome [220757/Z/20/Z] and the National
- 352 Institute for Health Research (NIHR) [16/136/46]. KCJ is supported by an MRC African
- 353 Research Leader award [MR/T008822/1]. RSH is a NIHR senior investigator. The views
- 354 expressed in this publication are those of the authors and not necessarily those of the NIHR
- 355 or the UK government. A Wellcome Strategic award number 206545/Z/17/Z supports MLW.
- 356 The funders were not involved in the design of the study; in the collection, analysis, and
- 357 interpretation of the data; and in writing the manuscript.
- 358

## 359 **DECLARATION OF INTEREST**

360 All other authors declare no conflict of interest.

361

## 362 **REFERENCE**

- 363 1. JHU. COVID-19 Case Tracker 2020. <u>https://coronavirus.jhu.edu/map.html</u>.
- 2. Lewis H, Ware H, Whelan M, et al. SARS-CoV-2 infection in Africa: A systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. *medRxiv* 2022: 2022.02.14.22270934.
- 367 3. Organization WH. Africa COVID-19 vaccination dashboard. 2022.
   368 <u>https://app.powerbi.com/view?r=eyJrIjoiY2ViYzIyZjItYzhkMi00ZWVkLTgyM2ItZTk1ZTJmODR</u>
   369 jMTkxIiwidCl6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9.
- WHO. End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance. *Global influenza programme*, 2022. (accessed.
- Mandolo J, Msefula J, Henrion MYR, et al. SARS-CoV-2 exposure in Malawian blood
  donors: an analysis of seroprevalence and variant dynamics between January 2020 and July
  2021. *BMC Med* 2021; **19**(1): 303.
- PHIM. Daily COVID--19 Situation Report. Lilongwe: Public Health Institute of Malawi,
   Ministry of Health, 2020.
- 377 7. Estimating global, regional, and national daily and cumulative infections with SARS378 CoV-2 through Nov 14, 2021: a statistical analysis. *Lancet* 2022.
- 379 8. WHO. COVID-19 vaccine tracker and landscape. 2021.
- 380 <u>https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</u>.
  381 9. WHO. Coronavirus disease (COVID-19). 2022. <u>https://www.who.int/health-</u>
- 382 <u>topics/coronavirus#tab=tab 3</u>.
- 383 10. CDC. Symptoms of COVID-19. 2022. <u>https://www.cdc.gov/coronavirus/2019-</u>
   384 <u>ncov/symptoms-testing/symptoms.html</u>.
- Maze MJ, Bassat Q, Feasey NA, Mandomando I, Musicha P, Crump JA. The
  epidemiology of febrile illness in sub-Saharan Africa: implications for diagnosis and
  management. *Clin Microbiol Infect* 2018; **24**(8): 808-14.
- 388 12. Elven J, Dahal P, Ashley EA, et al. Non-malarial febrile illness: a systematic review of
- published aetiological studies and case reports from Africa, 1980-2015. *BMC Med* 2020;

**18**(1): 279.

391 13. Morton B, Barnes KG, Anscombe C, et al. Distinct clinical and immunological profiles 392 of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. Nat Commun 2021; 393 **12**(1): 3554. 394 14. ISARIC. COVID-19 CRF. 2022. https://isaric.org/research/covid-19-clinical-research-395 resources/covid-19-crf/. 396 Anscombe C, Lissauer S, Thole H, et al. Genomically informed clinical comparison of 15. 397 three epidemic waves of COVID-19 in Malawi. medRxiv 2022: 2022.02.17.22269742. 398 ARTIC field bioinformatics pipeline. 2022. https://github.com/artic-16. 399 network/fieldbioinformatics. 400 Simulundu E, Mupeta F, Chanda-Kapata P, et al. First COVID-19 case in Zambia -17. 401 Comparative phylogenomic analyses of SARS-CoV-2 detected in African countries. 402 International journal of infectious diseases : IJID : official publication of the International 403 Society for Infectious Diseases 2021; **102**: 455-9. 404 18. O'Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an 405 emerging pandemic using the pangolin tool. *Virus Evol* 2021; **7**(2): veab064. 406 19. Amberbir A, Lin SH, Berman J, et al. Systematic Review of Hypertension and Diabetes 407 Burden, Risk Factors, and Interventions for Prevention and Control in Malawi: The NCD BRITE Consortium. *Glob Heart* 2019; **14**(2): 109-18. 408 409 20. Price AJ, Crampin AC, Amberbir A, et al. Prevalence of obesity, hypertension, and 410 diabetes, and cascade of care in sub-Saharan Africa: a cross-sectional, population-based 411 study in rural and urban Malawi. Lancet Diabetes Endocrinol 2018; 6(3): 208-22. 21. 412 Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of 413 hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and 414 delta variant dominance: a prospective observational study from the ZOE COVID Study. 415 Lancet 2022; 399(10335): 1618-24. 416 22. Whitaker M, Elliott J, Bodinier B, et al. Variant-specific symptoms of COVID-19 417 among 1,542,510 people in England. medRxiv 2022: 2022.05.21.22275368. 418 Vihta K-D, Pouwels KB, Peto TE, et al. Omicron-associated changes in SARS-CoV-2 23. 419 symptoms in the United Kingdom. medRxiv 2022: 2022.01.18.22269082. 420 Madhi SA, Kwatra G, Myers JE, et al. Population Immunity and Covid-19 Severity with 24. 421 Omicron Variant in South Africa. N Engl J Med 2022. 422 Hui KPY, Ho JCW, Cheung MC, et al. SARS-CoV-2 Omicron variant replication in 25. 423 human bronchus and lung ex vivo. Nature 2022; 603(7902): 715-20. 424 Lewis D. Will Omicron finally overpower China's COVID defences? Nature. 2022. 26. 425 27. Tso WWY, Kwan M, Wang LY, et al. Intrinsic Severity of SARS-CoV-2 Omicron BA.2 in 426 Uninfected, Unvaccinated Children: A Population-Based, Case-Control Study on Hospital 427 Complications. SSRN 2022. 428 Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines 28. against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and 429 430 meta-regression. Lancet 2022; 399(10328): 924-44. 431 Wilkinson E, Giovanetti M, Tegally H, et al. A year of genomic surveillance reveals 29. 432 how the SARS-CoV-2 pandemic unfolded in Africa. *Science*; **0**(0): eabj4336. 433 NSO. Malawi Population and Housing Census. Zomba: National Statistical Office, 30. 434 Malawi, 2018. 435 436

437	FIGURE LEGENDS
438	Figure 1. Prevalence of SARS-CoV-2 infections. A) Prevalence of SARS-CoV-2 infections
439	across age groups. B) Prevalence of SARS-CoV-2 infections over time. Grey area represents
440	confidence intervals. C) SARS-CoV-2 variants of concern across the three pandemic waves.
441	D) SARS-CoV-2 variants of concern across age groups. (n=402)
442	
443	Figure 2. Clinical symptoms associated with PCR-confirmed SARS-CoV-2 infection.
444	Differences in clinical symptoms of PCR-confirmed SARS-CoV-2 infected adults during the
445	Omicron and Pre-Omicron phases (n=447).
446	
447	
448	
449	
450	
451	
452	
453	
454	
455	
456	
457	
458	
459	
460	
461	
462	
463	
464 465	
465 466	
460 467	
467	

## 469 **TABLES**

## 470 Table 1. Participant characteristics for main cohort

Characteristic         N = 5,176 <sup>1</sup> Sex         Female         2,596 (50%)           473         Male         2,580 (50%)           474         Male         2,580 (50%)           475         Age group         476           477         1.0-5 years         331 (6.4%)           2.6-12 years         228 (4.4%)           3.13-17 years         249 (4.8%)           478         3.13-17 years         249 (4.8%)           479         4.18-50 years         368 (7.1%)           480         5.51+ years         368 (7.1%)           481         SARS-CoV-2 PCR positivity           482         Negative         3,992 (77%)           90         1,184 (23%)         1 n (%); Median (IQR)           484         485         486           487         488         489           490         491         492           493         494         495           493         494         495           496         497         498           499         499         499           500         500         500	471		
473       Female       2,596 (50%)         474       Male       2,580 (50%)         475       Age group       476         476       Age group       1.0-5 years       331 (6.4%)         477       2.6-12 years       228 (4.4%)         478       3.13-17 years       249 (4.8%)         479       4.18-50 years       4,000 (77%)         480       5.51+ years       368 (7.1%)         481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         Positive       1,184 (23%)         7 n (%); Median (IQR)       484         485       486         487       488         488       489         490       491         492       493         493       494         495       496         497       498         498       499         499       496         494       495         495       496         497       498         498       499         499       496         499       496         499       496	472		N = 5,176 <sup>7</sup>
474       Male       2,580 (50%)         475       Age group       476         476       Age group       1.0-5 years       331 (6.4%)         477       2.6-12 years       228 (4.4%)         478       3.13-17 years       249 (4.8%)         479       4.18-50 years       4,000 (77%)         480       5.51+ years       368 (7.1%)         481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         Positive       1,184 (23%)         483 <sup>1</sup> n (%); Median (IQR)         484       485         485       486         487       488         488       489         490       491         492       493         493       494         495       496         497       498         498       499         499       498         499       499	473		2 506 (50%)
Age         28 (21, 38)           476         Age group           477         1.0-5 years         331 (6.4%)           478         3.13-17 years         228 (4.4%)           478         3.13-17 years         249 (4.8%)           479         4.18-50 years         4,000 (77%)           480         5.51+ years         368 (7.1%)           481         SARS-CoV-2 PCR positivity           482         Negative         3,992 (77%)           483         7 n (%); Median (IQR)         3,992 (77%)           483         7 n (%); Median (IQR)         484           485         486         487           486         487         488           489         490         491           492         493         494           495         496         497           498         499         496           497         498         499	474		
Age group         477       1.0-5 years       331 (6.4%)         477       2.6-12 years       228 (4.4%)         478       3.13-17 years       249 (4.8%)         479       4.18-50 years       4,000 (77%)         480       5.51+ years       368 (7.1%)         481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         90       4.184 (23%)       1,184 (23%)         483       1 n (%); Median (IOR)       484         485       486       487         488       489       489         490       491       493         493       494       495         493       494       495         494       495       496         497       498       499         499       499       499			
1. 0-5 years       331 (6.4%)         2. 6-12 years       228 (4.4%)         3. 13-17 years       249 (4.8%)         477       4. 18-50 years       4,000 (77%)         480       5. 51+ years       368 (7.1%)         481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         90       4.18-50 years       3,992 (77%)         483 <sup>1</sup> n (%); Median (IQR)       1,184 (23%)         484 <sup>1</sup> n (%); Median (IQR)       484         485       486       487         488       489       490         490       491       492         493       494       495         496       497       498         499       495       498         499       499       498         499       499       499         499       499       499         499       499       499         499       499       499         499       499       499         499       499       499         499       499       499         499       499       499         499 </td <td></td> <td></td> <td>20 (21, 00)</td>			20 (21, 00)
477       2. 6-12 years       228 (4.4%)         478       3. 13-17 years       249 (4.8%)         479       4. 18-50 years       4,000 (77%)         480       5. 51+ years       368 (7.1%)         481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         483       7 n (%); Median (IQR)       1,184 (23%)         484       485       486         485       486       487         488       489       490         490       491       492         493       494       495         496       497       498         499       499       498	476		331 (6.4%)
478       3. 13-17 years       249 (4.8%)         479       4. 18-50 years       4,000 (77%)         480       5. 51+ years       368 (7.1%)         481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         483 <sup>1</sup> n (%); Median (IQR)         484 <sup>1</sup> n (%); Median (IQR)         485       486         487       488         489       490         491       492         493       494         495       496         497       498         499       499	477	-	
480       5.51+ years       368 (7.1%)         481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         483 <sup>1</sup> n (%); Median (IQR)         484         485         486         487         488         489         490         491         492         493         494         495         496         497         498         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499         499	478	3. 13-17 years	249 (4.8%)
481       SARS-CoV-2 PCR positivity         482       Negative       3,992 (77%)         483       7 n (%); Median (IQR)       1,184 (23%)         483       7 n (%); Median (IQR)       484         485       485       485         488       487       488         489       489       490         490       491       492         493       493       493         494       495       494         495       496       497         498       499       499         499       499       499	479	4. 18-50 years	4,000 (77%)
481       Negative       3,992 (77%)         482       Positive       1,184 (23%)         483       'n (%); Median (IQR)         484       485         486       486         487       488         489       490         490       491         492       493         493       494         495       496         497       498         499       499	480	5. 51+ years	368 (7.1%)
482       Positive       1,184 (23%)         483 <sup>1</sup> n (%); Median (IQR)         484         485         486         487         488         489         490         491         492         493         494         495         496         497         498         499	481	SARS-CoV-2 PCR posit	ivity
Positive       1,184 (23%)         483       1 n (%); Median (IQR)         484       485         485       486         487       488         488       489         490       491         492       493         493       494         495       496         497       498         499       499	482	Negative	3,992 (77%)
484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499			1,184 (23%)
<ul> <li>485</li> <li>486</li> <li>487</li> <li>488</li> <li>489</li> <li>490</li> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>		<sup>1</sup> n (%); Median (IQR)	
<ul> <li>486</li> <li>487</li> <li>488</li> <li>489</li> <li>490</li> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>			
<ul> <li>487</li> <li>488</li> <li>489</li> <li>490</li> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>	485		
<ul> <li>488</li> <li>489</li> <li>490</li> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>	486		
<ul> <li>489</li> <li>490</li> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>	487		
<ul> <li>490</li> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>	488		
<ul> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>	489		
<ul> <li>491</li> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>	490		
<ul> <li>492</li> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>			
<ul> <li>493</li> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>			
<ul> <li>494</li> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>			
<ul> <li>495</li> <li>496</li> <li>497</li> <li>498</li> <li>499</li> </ul>			
496 497 498 499			
497 498 499	495		
498 499	496		
499	497		
	498		
500	499		
	500		

# 501 Table 2. Symptoms associated with SARS-CoV-2 infection

			Omic	ron)			Om	icron)	re-	Mu (Pr	e-Omio			OV-2 PCR I	Result (On	nicron)	Univ	ariate	e (Omi	cron)		ultiva Omic	
Chara	cteristic	Overall, N = 1,311 <sup>1</sup>	<b>Negative</b> , N = 1,157 <sup>1</sup>	Positive, N = 154 <sup>1</sup>	p- value <sup>2</sup>	N	OR <sup>3</sup>	95% Cl <sup>3</sup>	p- value	OR <sup>3</sup>	95% Cl <sup>3</sup>	p- value	Overall, N = 1,198 <sup>1</sup>	Negative, N = 870 <sup>1</sup>	Positive, N = 328 <sup>1</sup>	p- value <sup>2</sup>	N	OR <sup>3</sup>	95% Cl <sup>3</sup>	p- value	OR <sup>3</sup>	95% Cl <sup>3</sup>	
Fever		229 (17%)	207 (18%)	22 (14%)	0.3	1,311							217 (18%)	148 (17%)	69 (21%)	0.11	1,198						
No							Ref.	-		Ref.	-							Ref.	-		Ref.	-	
Yes							0.76	0.46, 1.21	0.3	0.65	0.39, 1.05	0.093						1.30	0.94, 1.78	0.11	1.23	0.88 1.71	
Cough	n	893 (68%)	784 (68%)	109 (71%)	0.5	1,311							654 (55%)	477 (55%)	177 (54%)	0.8	1,198						
No							Ref.	— 0.80,		Ref.	-							Ref.	— 0.75,		Ref.		
Yes		94					1.15	1.68	0.5	1.50	1.00, 2.30	0.056	22		44			0.97	1.25	0.8	1.04	1.38	
Fatigu	e	(7.2%)	73 (6.3%)	21 (14%)	<0.001	1,311				- (			32 (2.7%)	21 (2.4%)	11 (3.4%)	0.4	1,198				- í		
No Yes							Ref.	— 1.37, 3.87	0.001	Ref.		0.003						Ref.	- 0.65,	0.4	Ref.	0.55	
	of smell	62	53 (4.6%)	0 (5 9%)	0.5	1,311	2.04	3.87	0.001	2.27	3.86	0.000	25	16 (1.8%)	Q (2 7%)	0.3	1,198		2.89	0.4		2.64	
No	i sinen	(4.7%)	55 (4.078)	9 (3.076)	0.0	1,511	Ref.	_		Ref.	_		(2.1%)	10 (1.070)	3 (2.7 70)	0.5	1,130	Ref.	_		Ref.	_	
Yes							1.29	0.59, 2.55	0.5	0.89	0.34, 2.16	0.8						1.51	0.63, 3.38	0.3	0.70	0.22 2.06	
Loss c	of taste	86 (6.6%)	70 (6.1%)	16 (10%)	0.041	1,311		2.00			2.10		37 (3.1%)	21 (2.4%)	16 (4.9%)	0.028	1,198		0.00			2.00	
No		(0.078)					Ref.	_		Ref.	_		(3.170)		(4.570)			Ref.	-		Ref.	_	
Yes							1.80	0.99, 3.11	0.044	1.79	0.83, 3.65	0.12						2.07	1.05, 4.01	0.031	2.04	0.81 5.13	
Sore t	hroat	154 (12%)	134 (12%)	20 (13%)	0.6	1,311							161 (13%)	108 (12%)	53 (16%)	0.090	1,198						
No							Ref.	-		Ref.	-							Ref.	-		Ref.	_	
Yes							1.14	0.67, 1.85	0.6	1.03	0.59, 1.72	>0.9						1.36	0.95, 1.93	0.091	1.35	0.93 1.93	
Heada	iche	501 (38%)	426 (37%)	75 (49%)	0.004	1,311							389 (32%)	261 (30%)	128 (39%)	0.003	1,198						
No							Ref.	-		Ref.	-							Ref.	-		Ref.	- 1.07,	
Yes		270	233	37			1.63	1.16, 2.28	0.005	1.64	1.15, 2.34	0.007	343	0.05	108			1.49	1.14, 1.95	0.003	1.41	1.86	
	e ache	(21%)	(20%)	(24%)	0.3	1,311	Ref.	_		Ref.			(29%)	235 (27%)	(33%)	0.043	1,198	Ref.	_		Ref.		
No Yes							Ref.	0.83,	0.3	Rel.	- 0.72,	0.6						кег. 1.33	1.01,	0.044		0.94	
Joint	nain	105	89 (7.7%)	16 (10%)	0.2	1 311		1.85			1.80		75	49 (5.6%)	26	0.14	1 198		1.74			1.73	
No		(8.0%)	00 (/// /0)	10 (1070)	0.2	.,011	Ref.	_		Ref.	_		(6.3%)	40 (0.070)	(7.9%)	0.1-1	1,100	Ref.	_		Ref.	_	
Yes							1.39	0.77, 2.38	0.2	1.07	0.54, 2.01	0.8						1.44	0.87, 2.34	0.15	1.00	0.57	
Abdor pain	ninal	159 (12%)	137 (12%)	22 (14%)	0.4	1,311							96 (8.0%)	68 (7.8%)	28 (8.5%)	0.7	1,198						
No		. ,		. ,			Ref.	-		Ref.	-		. ,					Ref.	-		Ref.	-	
Yes							1.24	0.75, 1.98	0.4	1.33	0.76, 2.23	0.3						1.10	0.69, 1.72	0.7	1.29	0.79 2.08	
Diarrh	oea	102 (7.8%)	92 (8.0%)	10 (6.5%)	0.5	1,311							82 (6.8%)	63 (7.2%)	19 (5.8%)	0.4	1,198						
No							Ref.	-		Ref.	-							Ref.	-		Ref.	-	
Yes							0.80	0.39, 1.51	0.5	0.89	0.41, 1.78	0.8						0.79	0.45, 1.31	0.4	0.87	0.49 1.49	
Shorti breath	ness of N	108 (8.2%)	100 (8.6%)	8 (5.2%)	0.14	1,311							86 (7.2%)	66 (7.6%)	20 (6.1%)	0.4	1,198						
No							Ref.	 0.25, 1.14	0.15	Ref.	- 0.23,	0.14						Ref.	- 0.46,	0.4	Ref. 0.80	0.41	
Yes		244	/				0.58	1.14	0.15	0.55	0.23, 1.15	0.14	156	108	48			0.79	1.30	0.4	0.80	1.52	
Chest No	pain	(19%)	217 (19%)	27 (18%)	0.7	1,311	Ref.	_		Ref.	_		(13%)	(12%)	(15%)	0.3	1,198	Ref.	_		Ref.	_	
Yes								0.58, 1.41	0.7		0.51	0.5							0.83, 1.74	0.3	1.32		
Runny	nose	416	372	44	0.4	1.311		1.41			1.32		261	191 (22%)	70 (21%)	0.8	1,198		1.74			1.93	
No		(32%)	(32%)	(29%)	0.4	.,011	Ref.	_		Ref.	_		(22%)	101 (2270)	, o (21, o)	0.0	1,100	Ref.	_		Ref.	_	
Yes							0.84	0.58, 1.21	0.4		0.52, 1.16	0.2						0.96	0.70, 1.31	0.8	0.96	0.69 1.32	
Pneun	nonia	80 (6.1%)	70 (6.1%)	10 (6.5%)	0.8	1,311							72 (6.0%)	57 (6.6%)	15 (4.6%)	0.2	1,198						
No							Ref.	-		Ref.	-							Ref.	-		Ref.	-	
								0.51, 2.05			0.67, 3.13								0.37, 1.19		0.78		

# 533 Table 3. Participant characteristics for PCR-confirmed SARS-CoV-2 infected adult patients

Female         232 (52%)         151 (50%)         81 (56%)           Male         215 (48%)         151 (50%)         64 (44%)           Age         31 (24, 39)         31 (25, 38)         32 (23, 39)           HIV status               Negative         277 (84%)         173 (83%)         104 (87%)            Positive         277 (84%)         173 (83%)         104 (87%)            Inknown         119         94         25            PLHIV on ART         49 (11%)         34 (11%)         15 (10%)            Diabetes         4 (0.9%)         0 (0%)         4 (2.8%)         O           O         310 (69%)         206 (68%)         7 (4.8%)         O           Q         310 (69%)         206 (68%)         104 (72%)         O           Q         310 (69%)         37 (12%)         26 (18%)         G           Q         310 (69%)         37 (12%)         26 (18%)         15 (10%)	Female         232 (52%)         151 (50%)         81 (5           Male         215 (48%)         151 (50%)         64 (4           Age         31 (24, 39)         31 (25, 38)         32 (23)           HIV status         Negative         277 (84%)         173 (83%)         104 (           Positive         51 (16%)         35 (17%)         16 (1)           Unknown         119         94         2           PLHIV on ART         49 (11%)         34 (11%)         15 (1)           Diabetes         4 (0.9%)         0 (0%)         4 (2)           O         310 (69%)         206 (68%)         104 (           1         63 (14%)         37 (12%)         26 (7)           2         74 (17%)         59 (20%)         15 (3)           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40)           Unknown         375         263         11           1 n (%); Median (IQR)         375         263         11		e-omicron phase,	, N = 145′ <b>F</b>	o-valu
Male         215 (48%)         151 (50%)         64 (44%)           Age         31 (24, 39)         31 (25, 38)         32 (23, 39)           HIV status         Negative         277 (84%)         173 (83%)         104 (87%)           Positive         51 (16%)         35 (17%)         16 (13%)           Unknown         119         94         25           PLHIV on ART         49 (11%)         34 (11%)         15 (10%)           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.4%)         2           Diabetes         4 (0.9%)         0 (0%)         4 (2.8%)         CO           O         310 (69%)         206 (68%)         104 (72%)         CO           0         310 (69%)         206 (68%)         104 (72%)         CO           0         310 (69%)         206 (68%)         104 (72%)         CO           0         310 (69%)         206 (68%)         104 (72%)         CO           1         63 (14%)         37 (12%)         26 (18%)         CO           2         74 (17%)         59 (20%)         15 (10%)         CO           1         63 (14%)         37 (12%)         78 (40, 137)         CO           2	Male         215 (48%)         151 (50%)         64 (4           Age         31 (24, 39)         31 (25, 38)         32 (23)           HIV status <th< th=""></th<>				0.2
Age         31 (24, 39)         31 (25, 38)         32 (23, 39)           HIV status         Negative         277 (84%)         173 (83%)         104 (87%)           Positive         51 (16%)         35 (17%)         16 (13%)         104 (87%)           Positive         51 (16%)         35 (17%)         16 (13%)         104 (87%)           Unknown         119         94         25         25           PLHIV on ART         49 (11%)         34 (11%)         15 (10%)         34           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.4%)         34           Diabetes         4 (0.9%)         0 (0%)         4 (2.8%)         0           O         310 (69%)         206 (68%)         104 (72%)         34           1         63 (14%)         37 (12%)         26 (18%)         37           1         63 (14%)         37 (12%)         26 (18%)         37           2         74 (17%)         59 (20%)         15 (10%)         34           10known         375         263         112	Age       31 (24, 39)       31 (25, 38)       32 (22)         HIV status       Negative       277 (84%)       173 (83%)       104 (         Positive       51 (16%)       35 (17%)       16 (1         Unknown       119       94       2         PLHIV on ART       49 (11%)       34 (11%)       15 (1         Hypertension       7 (1.6%)       5 (1.7%)       2 (1.         Diabetes       4 (0.9%)       0 (0%)       4 (2.         Asthma       15 (3.4%)       8 (2.6%)       7 (4.         COVID-19 vaccination (doses)       206 (68%)       104 (         1       63 (14%)       37 (12%)       26 (7.         2       74 (17%)       59 (20%)       15 (1.         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40)         Unknown       375       263       11         1 n (%); Median (IQR)       375       263       11	ō)	81 (56%)		
HIV status       HIV status         Negative       277 (84%)       173 (83%)       104 (87%)         Positive       51 (16%)       35 (17%)       16 (13%)         Unknown       119       94       25         PLHIV on ART       49 (11%)       34 (11%)       15 (10%)         Hypertension       7 (1.6%)       5 (1.7%)       2 (1.4%)         Diabetes       4 (0.9%)       0 (0%)       4 (2.8%)       0         O       0 (0%)       8 (2.6%)       7 (4.8%)       0         O       310 (69%)       206 (68%)       104 (72%)       0         1       63 (14%)       37 (12%)       26 (18%)       15 (10%)         2       74 (17%)       59 (20%)       15 (10%)       40         Unknown       375       263       112	HIV status         Negative       277 (84%)       173 (83%)       104 (         Positive       51 (16%)       35 (17%)       16 (1         Unknown       119       94       2         PLHIV on ART       49 (11%)       34 (11%)       15 (1         Hypertension       7 (1.6%)       5 (1.7%)       2 (1.         Diabetes       4 (0.9%)       0 (0%)       4 (2.         Asthma       15 (3.4%)       8 (2.6%)       7 (4.         COVID-19 vaccination (doses)       0       310 (69%)       206 (68%)       104 (         1       63 (14%)       37 (12%)       26 (7.4         2       74 (17%)       59 (20%)       15 (1.4         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40.4)         Unknown       375       263       11         1       (0.9)       375       263       11	ō)	64 (44%)		
Negative         277 (84%)         173 (83%)         104 (87%)           Positive         51 (16%)         35 (17%)         16 (13%)           Unknown         119         94         25           PLHIV on ART         49 (11%)         34 (11%)         15 (10%)           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.4%)         33           Diabetes         4 (0.9%)         0 (0%)         4 (2.8%)         0           Asthma         15 (3.4%)         8 (2.6%)         7 (4.8%)         0           0         310 (69%)         206 (68%)         104 (72%)         0           1         63 (14%)         37 (12%)         26 (18%)         15 (10%)           2         74 (17%)         59 (20%)         15 (10%)         4           Unknown         375         263         112	Negative         277 (84%)         173 (83%)         104 (           Positive         51 (16%)         35 (17%)         16 (1           Unknown         119         94         2           PLHIV on ART         49 (11%)         34 (11%)         15 (1           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.           Diabetes         4 (0.9%)         0 (0%)         4 (2.           Asthma         15 (3.4%)         8 (2.6%)         7 (4.           COVID-19 vaccination (doses)         0         310 (69%)         206 (68%)         104 (           1         63 (14%)         37 (12%)         26 (7         2         74 (17%)         59 (20%)         15 (1.5%)           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40)           Unknown         375         263         11	8)	32 (23, 39)	)	0.8
Positive         51 (16%)         35 (17%)         16 (13%)           Unknown         119         94         25           PLHIV on ART         49 (11%)         34 (11%)         15 (10%)           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.4%)         33           Diabetes         4 (0.9%)         0 (0%)         4 (2.8%)         O           Asthma         15 (3.4%)         8 (2.6%)         7 (4.8%)         O           O         310 (69%)         206 (68%)         104 (72%)         O           1         63 (14%)         37 (12%)         26 (18%)         C           2         74 (17%)         59 (20%)         15 (10%)         C           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40, 137)         C           Unknown         375         263         112	Positive         51 (16%)         35 (17%)         16 (1           Unknown         119         94         2           PLHIV on ART         49 (11%)         34 (11%)         15 (1           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.           Diabetes         4 (0.9%)         0 (0%)         4 (2.           Asthma         15 (3.4%)         8 (2.6%)         7 (4.           COVID-19 vaccination (doses)         0         310 (69%)         206 (68%)         104 (1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.				0.4
Unknown         119         94         25           PLHIV on ART         49 (11%)         34 (11%)         15 (10%)           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.4%)         32           Diabetes         4 (0.9%)         0 (0%)         4 (2.8%)         0           Asthma         15 (3.4%)         8 (2.6%)         7 (4.8%)         0           O         310 (69%)         206 (68%)         104 (72%)         0           1         63 (14%)         37 (12%)         26 (18%)         0           2         74 (17%)         59 (20%)         15 (10%)         <           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40, 137)         <           1 n (%); Median (IQR)         375         263         112	Unknown         119         94         2           PLHIV on ART         49 (11%)         34 (11%)         15 (1           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.           Diabetes         4 (0.9%)         0 (0%)         4 (2.           Asthma         15 (3.4%)         8 (2.6%)         7 (4.           COVID-19 vaccination (doses)         0         310 (69%)         206 (68%)         104 (           1         63 (14%)         37 (12%)         26 (         2           2         74 (17%)         59 (20%)         15 (1           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40           Unknown         375         263         11	6)	104 (87%)		
PLHIV on ART         49 (11%)         34 (11%)         15 (10%)           Hypertension         7 (1.6%)         5 (1.7%)         2 (1.4%)         32           Diabetes         4 (0.9%)         0 (0%)         4 (2.8%)         0           Asthma         15 (3.4%)         8 (2.6%)         7 (4.8%)         0           COVID-19 vaccination (doses)         206 (68%)         104 (72%)         0           0         310 (69%)         206 (68%)         104 (72%)         0           1         63 (14%)         37 (12%)         26 (18%)         0           2         74 (17%)         59 (20%)         15 (10%)            Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40, 137)            1         375         263         112	PLHIV on ART       49 (11%)       34 (11%)       15 (1         Hypertension       7 (1.6%)       5 (1.7%)       2 (1.         Diabetes       4 (0.9%)       0 (0%)       4 (2.         Asthma       15 (3.4%)       8 (2.6%)       7 (4.         COVID-19 vaccination (doses)       0       310 (69%)       206 (68%)       104 (         0       310 (69%)       206 (68%)       104 (       1         1       63 (14%)       37 (12%)       26 (         2       74 (17%)       59 (20%)       15 (         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40)         Unknown       375       263       11         1 n (%); Median (IQR)       375       263       11	)	16 (13%)		
Hypertension       7 (1.6%)       5 (1.7%)       2 (1.4%)       3         Diabetes       4 (0.9%)       0 (0%)       4 (2.8%)       0         Asthma       15 (3.4%)       8 (2.6%)       7 (4.8%)       0         COVID-19 vaccination (doses)       206 (68%)       104 (72%)       0         0       310 (69%)       206 (68%)       104 (72%)       0         1       63 (14%)       37 (12%)       26 (18%)       0         2       74 (17%)       59 (20%)       15 (10%)          Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40, 137)          Unknown       375       263       112	Hypertension       7 (1.6%)       5 (1.7%)       2 (1.         Diabetes       4 (0.9%)       0 (0%)       4 (2.         Asthma       15 (3.4%)       8 (2.6%)       7 (4.         COVID-19 vaccination (doses)       0       310 (69%)       206 (68%)       104 (         1       63 (14%)       37 (12%)       26 (7.         2       74 (17%)       59 (20%)       15 (1.         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40.         Unknown       375       263       11		25		
Diabetes       4 (0.9%)       0 (0%)       4 (2.8%)       C         Asthma       15 (3.4%)       8 (2.6%)       7 (4.8%)       C         COVID-19 vaccination (doses)       0       310 (69%)       206 (68%)       104 (72%)       0         0       310 (69%)       206 (68%)       104 (72%)       0         1       63 (14%)       37 (12%)       26 (18%)       0         2       74 (17%)       59 (20%)       15 (10%)          Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40, 137)       <         Unknown       375       263       112	Diabetes         4 (0.9%)         0 (0%)         4 (2.           Asthma         15 (3.4%)         8 (2.6%)         7 (4.           COVID-19 vaccination (doses)         0         310 (69%)         206 (68%)         104 (           1         63 (14%)         37 (12%)         26 (7.         2         74 (17%)         59 (20%)         15 (1.           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40.           Unknown         375         263         11           1 n (%); Median (IQR)         37         263         11	)	15 (10%)		0.8
Asthma       15 (3.4%)       8 (2.6%)       7 (4.8%)         COVID-19 vaccination (doses)       0         0       310 (69%)       206 (68%)       104 (72%)         1       63 (14%)       37 (12%)       26 (18%)         2       74 (17%)       59 (20%)       15 (10%)         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40, 137)       <         Unknown       375       263       112	Asthma         15 (3.4%)         8 (2.6%)         7 (4.           COVID-19 vaccination (doses)         0         310 (69%)         206 (68%)         104 (           1         63 (14%)         37 (12%)         26 (7           2         74 (17%)         59 (20%)         15 (1           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40           Unknown         375         263         11	)	2 (1.4%)		>0.9
COVID-19 vaccination (doses)         0           0         310 (69%)         206 (68%)         104 (72%)           1         63 (14%)         37 (12%)         26 (18%)           2         74 (17%)         59 (20%)         15 (10%)           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40, 137)         <	COVID-19 vaccination (doses)         0       310 (69%)       206 (68%)       104 (         1       63 (14%)       37 (12%)       26 (1         2       74 (17%)       59 (20%)       15 (1         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40         Unknown       375       263       11         1 n (%); Median (IQR)       100       100       100		4 (2.8%)		0.011
0       310 (69%)       206 (68%)       104 (72%)         1       63 (14%)       37 (12%)       26 (18%)         2       74 (17%)       59 (20%)       15 (10%)         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40, 137)       <	0         310 (69%)         206 (68%)         104 (           1         63 (14%)         37 (12%)         26 (7           2         74 (17%)         59 (20%)         15 (1           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40           Unknown         375         263         11	)	7 (4.8%)		0.3
1       63 (14%)       37 (12%)       26 (18%)         2       74 (17%)       59 (20%)       15 (10%)         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40, 137)       <         Unknown       375       263       112 <sup>1</sup> n (%); Median (IQR)       1       1       1       1	1       63 (14%)       37 (12%)       26 (1         2       74 (17%)       59 (20%)       15 (1         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40         Unknown       375       263       11         1 n (%); Median (IQR)       1       1       1				0.02
2       74 (17%)       59 (20%)       15 (10%)         Days since last vaccine dose       137 (51, 187)       173 (141, 208)       78 (40, 137)       <	2         74 (17%)         59 (20%)         15 (1           Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40           Unknown         375         263         11           1 n (%); Median (IQR)         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1 <th1< th="">         1         <th< td=""><td>6)</td><td>104 (72%)</td><td></td><td></td></th<></th1<>	6)	104 (72%)		
Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40, 137)         <0           Unknown         375         263         112 <sup>1</sup> n (%); Median (IQR)         112         112	Days since last vaccine dose         137 (51, 187)         173 (141, 208)         78 (40           Unknown         375         263         11 <sup>1</sup> n (%); Median (IQR)         100         100         100	)	26 (18%)		
Unknown 375 263 112 <sup>1</sup> n (%); Median (IQR)	Unknown 375 263 11 <sup>1</sup> n (%); Median (IQR)	)	15 (10%)		
<sup>1</sup> n (%); Median (IQR)	<sup>1</sup> n (%); Median (IQR)	08)	78 (40, 137)	)	<0.00
			112		

## 549 Table 4. COVID-19 vaccination and the risk of PCR-confirmed SARS-CoV-2 infection

0%) 1,4 0%) 10 0%) 11 0%) 1,4 %) 6	N = 1,627 <sup>1</sup> 408 (82%) 07 (75%) 12 (75%) 447 (82%) 58 (76%) 12 (72%)	1, N = 382 <sup>7</sup> 310 (18%) 35 (25%) 37 (25%) 316 (18%) 22 (24%) 44 (28%)	0.027	N 2,009 2,009	1.50 Ref. 1.48	95% Cl <sup>3</sup>  0.98, 2.20 1.00, 2.20   0.88, 2.39 1.23, 2.58	0.053 0.042 0.12	Ref. 1.10 1.11 Ref. 1.93	95% Cl <sup>3</sup>  0.39, 2.66 0.40, 2.57  0.74, 5.68 0.63, 4.34	0.8 0.8 0.2
0%) 10 0%) 11 0%) 1,4 %) 6	07 (75%) 12 (75%) 447 (82%) 58 (76%)	35 (25%) 37 (25%) 316 (18%) 22 (24%)	0.003	·	1.49 1.50 Ref. 1.48	1.00, 2.20 — 0.88, 2.39	0.042	1.10 1.11 Ref. 1.93	0.39, 2.66 0.40, 2.57 	0.8
0%) 10 0%) 11 0%) 1,4 %) 6	07 (75%) 12 (75%) 447 (82%) 58 (76%)	35 (25%) 37 (25%) 316 (18%) 22 (24%)		2,009	1.49 1.50 Ref. 1.48	1.00, 2.20 — 0.88, 2.39	0.042	1.10 1.11 Ref. 1.93	0.39, 2.66 0.40, 2.57 	0.8
0%) 11 0%) 1,4 %) 6	12 (75%) 147 (82%) 68 (76%)	37 (25%) 316 (18%) 22 (24%)		2,009	1.50 Ref. 1.48	1.00, 2.20 — 0.88, 2.39	0.042	1.11 Ref. 1.93	0.40, 2.57	0.8
0%) 1,4 %) 6	147 (82%) 58 (76%)	316 (18%) 22 (24%)		2,009	Ref. 1.48		0.12	Ref. 1.93	- 0.74, 5.68	0.2
%) 6	8 (76%)	22 (24%)		2,009	1.48			1.93		
%) 6	8 (76%)	22 (24%)			1.48			1.93		
,	. ,	. ,								
0%) 11	12 (72%)	44 (28%)			1.80	1.23, 2.58	0.002	154	0.62 4.24	0.4
								1.04	0.03, 4.34	0.4
			0.4	2,009						
0%) 80	03 (80%)	198 (20%)			Ref.	_		Ref.	_	
0%) 82	24 (82%)	184 (18%)			0.91	0.72, 1.13	0.4	0.84	0.67, 1.06	0.15
			0.13	2,009						
0%) 1,5	536 (81%)	368 (19%)			Ref.	_		Ref.	_	
0%) 9	91 (87%)	14 (13%)			0.64	0.35, 1.10	0.13	0.62	0.33, 1.09	0.12
			<0.001	2,009						
0%) 94	43 (87%)	137 (13%)			Ref.	_		Ref.	_	
0%) 68	84 (74%)	245 (26%)			2.47	1.96, 3.11	<0.001	2.56	2.02, 3.26	<0.001
	0%) s	91 (87%)           93 (87%)           943 (87%)	91 (87%)       14 (13%)         90%)       943 (87%)       137 (13%)	00%)       1,536 (81%)       368 (19%)         0%)       91 (87%)       14 (13%)         <0.001	00%)       1,536 (81%)       368 (19%)         0%)       91 (87%)       14 (13%)         <0.001 2,009	1,536 (81%)         368 (19%)         Ref.           0%)         91 (87%)         14 (13%)         0.64           <0.001	NO%)       1,536 (81%)       368 (19%)       Ref.          0%)       91 (87%)       14 (13%)       0.64       0.35, 1.10                 0%)       91 (87%)       14 (13%)       0.64       0.35, 1.10 <td>No%)       1,536 (81%)       368 (19%)       Ref.       -         0%)       91 (87%)       14 (13%)       0.64       0.35, 1.10       0.13         &lt;0.001</td> 2,009         0%)       943 (87%)       137 (13%)       Ref.       -	No%)       1,536 (81%)       368 (19%)       Ref.       -         0%)       91 (87%)       14 (13%)       0.64       0.35, 1.10       0.13         <0.001	No%)       1,536 (81%)       368 (19%)       Ref.       -       Ref.         0%)       91 (87%)       14 (13%)       0.64       0.35, 1.10       0.13       0.62         <0.001	Now       1,536 (81%)       368 (19%)       Ref.       -       Ref.       -         0%)       91 (87%)       14 (13%)       0.64       0.35, 1.10       0.13       0.62       0.33, 1.09              Ref.       -       Ref.       -         0%)       91 (87%)       14 (13%)       0.64       0.35, 1.10       0.13       0.62       0.33, 1.09             Ref.        Ref.        Ref.          00%)       943 (87%)       137 (13%)       Ref.       -       Ref.       -       Ref.       -

<sup>3</sup> OR = Odds Ratio, CI = Confidence Interval

---


# 567 Table 5. Prevalence of symptoms among PCR-confirmed SARS-CoV-2 infected adult

## 568 patients during Omicron and pre-Omicron phases

		Propo					Univariate			Multivaria	
Characteristic			2 <sup>1</sup> Pre-omicron phase, N = 1	-		OR	95% Cl <sup>3</sup>	p-value	OK.	95% CI°	P
Fever	77 (17%)	58 (19%)	19 (13%)	0.11	447	- /					
No						Ref.			Ref.	_	
Yes						1.58	0.91, 2.82	0.11	2.33	1.23, 4.66	
Cough	264 (59%)	162 (54%)	102 (70%)	<0.001	447						
No						Ref.	-		Ref.	-	
Yes						0.49	0.32, 0.74	<0.001	0.36	0.21, 0.60	
Fatigue	32 (7.2%)	11 (3.6%)	21 (14%)	<0.001	447						
No						Ref.	-		Ref.	-	
Yes						0.22	0.10, 0.47	<0.001	0.18	0.07, 0.41	
Loss of smell	16 (3.6%)	8 (2.6%)	8 (5.5%)	0.13	447						
No						Ref.	_		Ref.	_	
Yes						0.47	0.17, 1.29	0.13	0.45	0.10, 1.97	
Loss of taste	30 (6.7%)	15 (5.0%)	15 (10%)	0.033	447						
No						Ref.	_		Ref.	_	
Yes							0.21, 0.96	0.037		0.27, 2.51	
Sore throat	64 (14%)	47 (16%)	17 (12%)	0.3	447		, 5.00			, 2.01	
No	0.(1770)	(1070)	.7 (1270)	0.0		Ref.	_		Ref.	_	
								0.2			
Yes	100 (400()	110 (00%)	70 (500/)	0.000	447	1.39	0.78, 2.58	0.3	1.44	0.75, 2.86	-
Headache	190 (43%)	118 (39%)	72 (50%)	0.034	447	- /			- /		
No						Ref.	_		Ref.	-	
Yes						0.65	0.44, 0.97	0.035	0.47	0.29, 0.74	
Muscle ache	142 (32%)	106 (35%)	36 (25%)	0.029	447						
No						Ref.	-		Ref.	-	
Yes						1.64	1.06, 2.58	0.030	1.59	0.94, 2.76	
Joint pain	42 (9.4%)	26 (8.6%)	16 (11%)	0.4	447						
No						Ref.	-		Ref.	_	
Yes						0.76	0.40, 1.49	0.4	0.69	0.30, 1.61	
Abdominal pain	46 (10%)	25 (8.3%)	21 (14%)	0.043	447						
No						Ref.	_		Ref.	_	
Yes						0.53	0.29, 1.00	0.046	0.37	0.18, 0.76	
Diarrhoea	24 (5.4%)	14 (4.6%)	10 (6.9%)	0.3	447						
No						Ref.	_		Ref.	_	
Yes						0.66	0.29, 1.56	0.3		0.27, 1.82	
Shortness of breath	28 (6.3%)	20 (6.6%)	8 (5.5%)	0.7	447						
No	20 (0.070)	20 (0.070)	0 (0.070)	0.7	/	Ref.	_		Ref.	_	
								0.7			
Yes	70 (100)	40 (450()	07 (100()			1.21	0.54, 2.99	0.7	2.65	0.88, 8.76	
Chest pain	73 (16%)	46 (15%)	27 (19%)	0.4	447						
No						Ref.	_		Ref.	_	
Yes						0.79	0.47, 1.34	0.4	0.83	0.46, 1.53	
Runny nose	104 (23%)	65 (22%)	39 (27%)	0.2	447						
No						Ref.	-		Ref.	-	
Yes						0.75	0.47, 1.18	0.2	1.10	0.65, 1.90	
Pneumonia	24 (5.4%)	15 (5.0%)	9 (6.2%)	0.6	447						
No						Ref.	-		Ref.	-	
Yes						0.79	0.34, 1.92	0.6	0.35	0.11, 1.10	
Sex				0.2	447						
Female	232 (52%)	151 (50%)	81 (56%)			Ref.	_		Ref.	_	
Male	215 (48%)	151 (50%)	64 (44%)			1.27	0.85, 1.89	0.2	1.38	0.89, 2.16	
Age	31 (24, 39)	31 (25, 38)	32 (23, 39)	0.8	447		0.98, 1.02			0.97, 1.02	
-			× - <i>i</i> /	0.5	447		,			,	
COVID-19 vaccinated				0.0							
COVID-19 vaccinated	310 (69%)	206 (68%)	104 (72%)			Ref.	_		Ref.	_	


## 599 FIGURES

## **Figure 1.**



- - -

## 619 Figure 2.




# 636 Supplementary Material

637

# 638 Supplementary Table 1.

	<b>Overall</b> , N = 35 <sup>1</sup>	<b>Omicron phase</b> , N = 26 <sup>1</sup>	<b>Pre-omicron phase</b> , N = 9 <sup>7</sup>	p-valu
Sex				0.5
Female	16 (46%)	13 (50%)	3 (33%)	
Male	19 (54%)	13 (50%)	6 (67%)	
Age group				0.3
<13 years	28 (80%)	22 (85%)	6 (67%)	
13-17 years	7 (20%)	4 (15%)	3 (33%)	
<b>Asthma</b> n (%)	1 (2.9%)	1 (3.8%)	0 (0%)	>0.9
<sup>2</sup> Fisher's exact te	est			

#### Supplementary Figure 1.



Supplementary Figure 1. Flowchart of participant enrolment and testing in two primary 

672 healthcare facilities in Blantyre City, Malawi, November 2020 – M	/larch 2022.
-----------------------------------------------------------------------	--------------